Zilovertamab vedotin is a novel antibody-drug conjugate (ADC) constructed by conjugating the humanized monoclonal antibody zilovertamab with the anti-microtubule cytotoxic drug monomethyl vedotin. It binds to ROR1 on the surface of tumor cells, promotes rapid internalization and trafficking of the complex to lysosomes, followed by ADC cleavage and release of monomethyl vedotin, thereby inducing tumor cell apoptosis. It can be used in cancer-related research.
Target:
Antibody-Drug Conjugates (ADCs)|||ROR
* VAT and and shipping costs not included. Errors and price changes excepted
